^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
3276 / 21 - Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in non-small cell lung cancer from East-Asian patients
Published date:
05/27/2020
Excerpt:
Based on East-Asian NSCLC patients, TIDE analysis revealed that for anti-PD-1/PD-L1 immunotherapy, EGFR-mutant and ALK-rearranged tumors may yield inferior responses; however, KRAS-mutant tumors may respond better...EGFR L858R-mutant tumors positively correlated with an inflammatory phenotype, suggesting responsiveness to anti-PD-1/PD-L1 immunotherapy.
